Ypsomed Sustainability Profile
Ypsomed Holding AG, commonly known as Ypsomed, is a leading Swiss company headquartered in Burgdorf, Switzerland (CH). Founded in 1984, Ypsomed has established itself as a key player in the medical technology industry, specialising in the development and manufacturing of innovative drug delivery systems and diabetes management solutions. With a strong presence in Europe and expanding operations in Asia and North America, Ypsomed is renowned for its cutting-edge products, including insulin delivery devices and pen systems. The company’s commitment to quality and user-centric design sets it apart in a competitive market. Ypsomed has achieved significant milestones, including partnerships with major pharmaceutical companies, solidifying its position as a trusted provider in the healthcare sector.
DitchCarbon Score
How does Ypsomed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ypsomed's score of 64 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ypsomed's reported carbon emissions
In 2024, Ypsomed reported total carbon emissions of approximately 128,294,000 kg CO2e, with Scope 1 emissions at about 2,198,000 kg CO2e and Scope 3 emissions at approximately 126,096,000 kg CO2e. The company has set ambitious climate commitments, aiming for net-zero CO2 emissions in its operations (Scope 1 and 2) by 2030 and across its entire value chain (Scope 1–3) by 2040. Ypsomed's reduction targets include a 90% reduction in absolute Scope 1 and 2 emissions by 2030 from a 2020 baseline, and a 32% reduction by 2027. Additionally, the company aims to reduce Scope 3 emissions by 52% per unit of million CHF value added by 2030 and by 97% per million CHF of value added by 2040. These targets are aligned with the Science Based Targets initiative (SBTi) and reflect Ypsomed's commitment to sustainable practices within the healthcare sector. The emissions data and targets are sourced from Ypsomed Holding AG, ensuring a comprehensive approach to climate accountability and transparency.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000 | - | 0,000 | 00,000 | - |
| Scope 3 | - | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 |
How Carbon Intensive is Ypsomed's Industry?
How Carbon Intensive is Ypsomed's Location?
Ypsomed's Scope 3 Categories Breakdown
Ypsomed's Scope 3 emissions, which increased by 11% last year and increased by approximately 11% since 2019, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 50% of Scope 3 emissions.
Top Scope 3 Categories
Ypsomed's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ypsomed has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
